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From Imitation to InnovationSpencer B. King III, MD, MACC, Editor-in-Chief, JACC: Cardiovascular InterventionsC hina is ancient, and yet it is brand new. Myﬁrst visit to China was with Willis Hurstand 2 others from Emory University in
1987. We spent more than 2 weeks visiting medical
schools and hospitals in 4 cities. Just recently,
I went to China as a guest of our publisher, Elsevier,
to visit cardiologists who are interested in publishing
their work. I visited 6 hospitals in 3 cities. Although I
have been to China many times over the past 27 years,
I could not escape the contrast between my ﬁrst visit
and this one: from Mao jackets to Paris fashions, and
from bicycles and rickshaws to Mercedes and Maser-
ati and buildings soaring to the sky. The medical facil-
ities have also transformed. Cardiac catheterization
laboratories in 1987 were few, and equipment was
barely functional, whereas today the latest imaging
systems are installed and the scale is massive. There
are about 16 catheterization laboratories in the
Fu Wai Hospital, but next year there will be 25.
The purpose of my visit was to talk about getting
published, but as I advised them, publishing papers in
highly-rated journals is over 90% dependent on the
project and <10% dependent on preparation of the
manuscript. A few years ago, the research projects in
China were rudimentary. Some massive trials were
accomplished with the involvement of major research
organizations, such as Oxford in the United Kingdom,
but the local research expertise is rapidly expanding.
I saw research activity from translational animal
experiments to large randomized clinical trials, and
I spent a good bit of time with investigators who
showed me their projects. In the clinical research area,
the tendency to submit review papers with or without
various meta-analyses is beginning to give way to the
submission of original research. During my visit, one
of the highly respected senior colleagues from China
advised his fellows to “forget about meta-analyses
and do your own research.” I perceived that there
are a number of unique opportunities for clinicalresearch in China. For one, the patient population is
never small. The early reluctance to randomization
that I had previously heard about no longer seems to
be present. Enrollment in large randomized trials in
multiple hospitals across the country seems to move
very fast. Subjects of great interest, such as anti-
coagulation schemes for primary percutaneous
coronary intervention for ST-segment elevation
myocardial infarction, have enrolled thousands in
patients in months. We discussed the fact that much
of the ﬁnancial support for clinical research around
the world will continue to come from industry spon-
sors. There is the opportunity to participate in such
studies while leveraging the large patient volume to
investigate more targeted questions by including pre-
speciﬁed substudies in the protocols. The opportunity
for investigator-initiated studies, I suspect, will also
increase as the government realizes the opportunity
from funding clinical research organizations. There is
still a long way to go in developing and funding
clinical research coordinators, core laboratories, and
other expertise. Although the tendency to imitate
technology that was developed elsewhere is widely
known, there are opportunities to address speciﬁc
questions with these technologies. A paper in this
issue of JACC: Cardiovascular Interventions reports
the comparison of a bioabsorbable polymer-coated
stent with a biostable one largely controlling for the
same drug (sirolimus) and the stent platform (1). That
study was presented at Transcatheter Cardiovascular
Therapeutics and was simultaneously published
ahead of print in this journal. There also appears to be
a great opportunity for outcomes research. Registries
are critical for this type of work, and, although there
are hospitals with well-developed registries, there is a
need for broad collaboration in creating regional and
national registries. Much of the work that has gone
into developing the American College of Cardiology’s
National Cardiovascular Data Registries is applicable
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1461and adaptable to China. The potential for cardiovas-
cular research in China is vast, and I, for one, welcome
the development of that capability. It is hoped that
progress in China will be a stimulus to those countries
with well-established research capabilities to invest
adequately in biomedical research. The recent reve-
lation that the Ebola outbreak requires not only a
major public health effort, but also a major push for
new drugs and vaccine research, has pointed the
spotlight on shrinking research funding for the
National Institutes of Health–sponsored laboratories.
We should not have to wait for dramatic events such
as the threat of Ebola to fund scientists and clinical
researchers who are committed to our greatest health
threat—cardiovascular disease.
In the area of device development, it is no secret
that imitation has dominated. Now, it is estimated
that 80% of the drug-eluting stents sold in China are
those locally produced. The same will be true for
heart valves and other devices. Patent protection isnot a priority in China, and it is not clear how the legal
questions surrounding development of like devices
would impede the availability of these products
outside China. One would hope, however, that some
of the energies that have gone into imitating existing
devices will be applied to innovating unique solu-
tions. In such a “young country” with very different
rules, it is not surprising that there is incentive
to reproduce what has been done elsewhere. That
is not all bad, as the methods of scientiﬁc inves-
tigation are universal. What I am seeing now in
clinical research and device development is a tran-
sition from imitation to innovation. It is the inno-
vation that will be publishable in leading medical
journals.
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